K. Rost

发表

Longitudinal assessment of a P‐glycoprotein–mediated drug interaction of valspodar on digoxin

J. Kovarik, J. Kovarik, M. Guerret, 1999, Clinical pharmacology and therapeutics.

Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.

W. Herrmann, D. Horwitz, K. Rost, 1999, International journal of clinical pharmacology and therapeutics.

Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment.

U. Mansmann, I. Roots, K. Rost, 1997, International journal of clinical pharmacology and therapeutics.

Lack of Effect of Gemifloxacin on the Steady-State Pharmacodynamics of Warfarin in Healthy Volunteers

K. Rost, H. Fuder, M. Davy, 1999, Chemotherapy.

The Effects of NN414, a SUR1/Kir6.2 Selective Potassium Channel Opener, in Healthy Male Subjects

T. Dyrberg, M. Zdravkovic, K. Rost, 2005, Journal of clinical pharmacology.

Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.

U. Fuhr, K. Rost, 1994, Pharmacogenetics.

Investigation of sarizotan’s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial

A. Kovar, H. Dolgos, S. Krösser, 2006, European Journal of Clinical Pharmacology.

Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.

J. Brockmöller, I. Roots, K. Rost, 1995, Pharmacogenetics.

Omeprazole weakly inhibits CYP1A2 activity in man.

U. Fuhr, J. Brockmöller, I. Roots, 1999, International journal of clinical pharmacology and therapeutics.

Lack of Effect of Gemifloxacin on the Steady-State Pharmacokinetics of Theophylline in Healthy Volunteers

K. Rost, H. Fuder, A. Allen, 1999, Chemotherapy.

Drug Interaction Profile and Low Phototoxic Potential of Gemifloxacin, a Potent Novel Fluoroquinolone Authors

K. Rost, Justin J. Richards, H. Fuder, 1999 .

Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics

T. Schaberg, H. Lode, P. Koeppe, 1995, Antimicrobial agents and chemotherapy.

Population kinetics of gentamicin in neonates

W. Weber, L. Harnisch, K. Rost, 2005, European Journal of Clinical Pharmacology.

Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.

P. Beaune, D. Grant, U. Fuhr, 1996, Pharmacogenetics (London).

Multiple‐dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers

J. Brockmöller, I. Roots, W. Weber, 1991, Clinical pharmacology and therapeutics.

The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes.

M. Zdravkovic, K. Rost, M. Kruse, 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Nonlinear kinetics after high‐dose omeprazole caused by saturation of genetically variable CYP2C19

I. Roots, K. Rost, K L Rost, 1996, Hepatology.

Specific and dose‐dependent enzyme induction by omeprazole in human beings

I. Roots, G. Heinemeyer, K. Rost, 1994, Hepatology.

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test

I. Roots, K. Rost, 1994, Clinical pharmacology and therapeutics.

Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin

J. Brockmöller, I. Roots, M. Scheffler, 1992, Clinical pharmacology and therapeutics.

Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.

J. Brockmöller, I. Roots, K. Rost, 1995, Journal of hepatology.

K. Rost, A. Handke, H. Kewitz, 1990, Neurochemistry International.

Theophylline metabolism affected by mexiletine

U. Fuhr, A. Staib, I. Roots, 1992, Clinical pharmacology and therapeutics.

Effect of different omeprazole doses combined with amoxicillin on intragastric pH, amoxicillin bioavailability and Helicobacter pylori eradication in duodenal ulcer patients

U. Marsch-Ziegler, W. Londong, K. Rost, 1995 .

Dose dependent induction of CYP1A2 activity by omeprazole (Antra).

I. Roots, M. Scheffler, K. Rost, 1992, International journal of clinical pharmacology, therapy, and toxicology.